Impax releases generic version of dutasteride capsules, 0.5 mg

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 24 2015Impax Laboratories, Inc.

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg. The Company immediately initiated commercialization activities through its generic division. This is the 13th generic product launched in 2015 by Impax's generic division.

According to IMS Health (NSP), U.S. brand and generic sales of dutasteride capsules, 0.5 mg were approximately $457 million for the 12 months ending in September 2015.

Source:

Impax Laboratories, Inc.

Posted in: Pharmaceutical News

Tags: , , , , , ,

Comments (0)

Suggested Reading

How medical manufacturing trends are evolving: From performance testing to 3D vision
LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities
Certain progestogens linked to higher brain tumor risk in women, study suggests
Revolutionary stem cell culture method produces full model of human central nervous system
Study highlights anti-inflammatory properties of herbal medicine, Erigeron breviscapus to treat osteoarthritis
Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
Interdisciplinary project aims to decode human kinome in brain function and disease
Overcoming adherence challenges: Innovative patch enables controlled drug delivery

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles